Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, explains that most multiple sclerosis (MS) patients infected with COVI-19 had a mild-moderate infection, with no more relapses or more severe disease course than MS-free patients. Furthermore, most MS patients produced a good response to vaccination with high antibody titers. On the other hand, anti-CD20 treatment increased COVID-19 disease severity, and both anti-CD20 and S1P1 treatment inhibited vaccine response and decreased antibody production in MS patients. This interview took place during the European Academy of Neurology 2021 congress.
C.Oreja-Guevara has received speaker and consultation fees from Biogen Idec, Celgene, Sanofi-Genzyme, Novartis, Roche, Merck, and Teva.